Hypogonadotropic Hypogonadism Management

Introduction to Treatment Options

Pulsatile GnRH therapy is more effective than exogenous gonadotropins in functional hypothalamic amenorrhea, as recommended by the European Society of Human Reproduction and Embryology and the Endocrine Society 1, 1
Pulsatile GnRH therapy can initiate and maintain spermatogenesis in men, according to the American Urological Association and the Endocrine Society 2, 1

For men, hCG injections can normalize testosterone levels, followed by FSH or FSH analogs to optimize sperm production, as suggested by the American Urological Association 2
For women, combined FSH and LH or hCG can be used for ovulation induction, as recommended by the European Society of Human Reproduction and Embryology 1

Aromatase inhibitors, hCG, selective estrogen receptor modulators (SERMs), or a combination may be used for infertile men with low serum testosterone, according to the American Urological Association 2
Testosterone monotherapy should not be prescribed for males interested in current or future fertility, as stated by the American Urological Association and the European Association of Urology 2, 3
For men with idiopathic infertility, FSH analogue treatment may improve sperm concentration, pregnancy rate, and live birth rate, as reported by the American Urological Association 2

Stress management, appropriate weight gain, and reduced exercise intensity can help address underlying causes of hypogonadotropic hypogonadism, as recommended by the European Society of Human Reproduction and Embryology 1
Lifestyle modifications, such as weight loss, increased physical activity, smoking cessation, healthy diet, and moderate alcohol consumption, should be the first-line approach for managing age-related testosterone decline, as they can increase total testosterone levels and reduce symptoms while avoiding potential risks of testosterone therapy, according to the American Urological Association 4

GnRH analogs can be used to preserve final adult height, delay menarche, and optimize development of secondary sex characteristics, as suggested by the American Society of Clinical Oncology 5
Treatment with GnRH analogs usually continues until the normal age of puberty, as reported by the American Society of Clinical Oncology 5

The following hormone levels should be measured:
Pelvic ultrasound in women can assess ovarian morphology 1
Morning cortisol measurement can help rule out adrenal insufficiency 7
Pre-treatment evaluation should include measurement of hemoglobin/hematocrit, assessment of cardiovascular risk factors, measurement of PSA in men over 40 years, and evaluation of fertility status and reproductive health, as suggested by The Journal of Urology 4

The Endocrine Society recommends the following tests to evaluate for associated conditions:

Test	Purpose
1 mg overnight dexamethasone suppression test	Evaluate for autonomous cortisol secretion [8]
Plasma ACTH	Determine if progesterone elevation is ACTH-dependent [8]
CT scan of adrenal glands	Evaluate for adrenal masses [8]
Aldosterone/renin ratio	If hypertension or hypokalemia is present [8]
Plasma or 24-hour urinary metanephrines	If pheochromocytoma is suspected [8]

Testosterone replacement therapy is a medical treatment that aims to restore normal testosterone levels in individuals with hypogonadism, as recommended by the European Association of Urology and the American Urological Association 3, 2
Testosterone replacement therapy is contraindicated in men seeking fertility, as it suppresses gonadotropins and spermatogenesis, according to the European Association of Urology and The Journal of Urology 3, 4
Testosterone replacement therapy (if indicated) should aim for a mid-normal range (450-600 ng/dL), and monitoring of hematocrit is necessary, with intervention needed if >54%, as recommended by The Journal of Urology 4

Regular monitoring of hormone levels (every 3-6 months initially) and addressing modifiable factors such as weight management, reduction of alcohol consumption, smoking cessation, and avoidance of exogenous testosterone is recommended 2
Regular follow-up with hormone measurements every 3-6 months initially, then annually, and repeat MRI imaging to assess tumor size, as well as monitoring for development of other pituitary hormone deficiencies, is crucial in managing gonadotropin-secreting pituitary adenoma 9